Whitehawk Therapeutics, Inc. (WHWK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated March 12, 2026, announces the financial results for Whitehawk Therapeutics, Inc. for the fiscal year ended December 31, 2025. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC under the symbol WHWK.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
No material changes versus the prior comparable period are detailed in the text of this filing. The document serves solely as a notification that the annual results have been issued.
Guidance, Outlook, and Risks
The filing does not contain specific management commentary, forward-looking guidance, risk factors, or unusual items. It explicitly states that the information furnished in Item 2.02 and Item 9.01 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liabilities of that section.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 12, 2026) for actual financial figures and operational highlights.
- Verify the company's cash runway and burn rate, as these are critical for a clinical-stage biopharmaceutical company but are not listed in this summary filing.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full press release.
- Confirm the status of the company's debt obligations and liquidity position from the full financial statements referenced in the press release.